Terminal Access

Unlimited access to the most powerful analytical tools in finance.

Bloomberg Fair Value
20M Securities
50Y History
10Y Estimates
8.000+ News Daily
Subscribe for $2
Overview
Profile

Cochlear stock

COH.AX
AU000000COH5
898321

Price

0
Today +/-
-0
Today %
-0 %

Cochlear stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Cochlear stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Cochlear stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Cochlear stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Cochlear's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Cochlear Stock Price History

DateCochlear Price
4/14/20250 undefined
4/11/2025250.58 undefined
4/10/2025257.85 undefined
4/9/2025250.03 undefined
4/8/2025256.36 undefined
4/7/2025253.48 undefined
4/4/2025268.94 undefined
4/3/2025268.83 undefined
4/2/2025269.34 undefined
4/1/2025264.81 undefined
3/31/2025263.62 undefined
3/28/2025266.85 undefined
3/27/2025268.63 undefined
3/26/2025268.82 undefined
3/25/2025265.71 undefined
3/24/2025266.90 undefined
3/21/2025271.00 undefined
3/20/2025270.65 undefined
3/19/2025270.26 undefined
3/18/2025268.44 undefined
3/17/2025263.63 undefined

Cochlear Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cochlear, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cochlear from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cochlear’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cochlear. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cochlear’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cochlear’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cochlear’s growth potential.

Cochlear Revenue, EBIT and net profit per share

DateCochlear RevenueCochlear EBITCochlear Net Income
2030e3.86 B undefined0 undefined734.59 M undefined
2029e3.56 B undefined906.45 M undefined673.65 M undefined
2028e3.3 B undefined834.08 M undefined622.7 M undefined
2027e2.95 B undefined713.19 M undefined534.13 M undefined
2026e2.68 B undefined629.99 M undefined471.71 M undefined
2025e2.44 B undefined553.18 M undefined415.28 M undefined
20242.24 B undefined531.6 M undefined356.8 M undefined
20231.94 B undefined411.6 M undefined300.6 M undefined
20221.65 B undefined394 M undefined289.1 M undefined
20211.5 B undefined355.9 M undefined326.5 M undefined
20201.32 B undefined241 M undefined-238.3 M undefined
20191.43 B undefined359.5 M undefined276.7 M undefined
20181.36 B undefined348 M undefined245.8 M undefined
20171.25 B undefined324.12 M undefined223.62 M undefined
20161.13 B undefined270.2 M undefined188.92 M undefined
2015925.63 M undefined215.36 M undefined145.84 M undefined
2014804.9 M undefined154.3 M undefined93.7 M undefined
2013752.7 M undefined182.9 M undefined132.6 M undefined
2012779 M undefined220.5 M undefined56.8 M undefined
2011809.6 M undefined246.9 M undefined180.1 M undefined
2010734.8 M undefined225.5 M undefined155.2 M undefined
2009694.7 M undefined177.1 M undefined130.5 M undefined
2008601.7 M undefined165 M undefined115.2 M undefined
2007559.4 M undefined153.6 M undefined100.1 M undefined
2006452.3 M undefined108.5 M undefined80 M undefined
2005348.5 M undefined80 M undefined54.5 M undefined

Cochlear Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (M)
NET INCOME GROWTH (%)
DIV. ()
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
0.070.070.090.130.150.220.260.290.290.350.450.560.60.690.730.810.780.750.80.931.131.251.361.431.321.51.651.942.242.442.682.953.33.563.86
--1.3727.7839.1314.0652.0515.3213.28-1.7222.1129.8923.677.5115.475.7610.22-3.71-3.476.9115.0522.1610.888.784.62-7.4313.4110.0917.4815.449.1310.009.9111.737.988.40
2,321.922,354.171,842.391,324.2274.6667.1271.4877.2473.3373.8571.0271.2072.3872.1973.3072.5674.4572.6169.4071.3571.9571.9973.7375.8874.5573.3575.8575.0575.8469.5063.1857.4851.4447.6443.95
00000.110.150.180.220.210.260.320.40.440.50.540.590.580.550.560.660.810.91.011.080.981.11.251.451.7000000
10101316203140583654801001151301551805613293145188223245276-238326289300356415471534622673734
--30.0023.0825.0055.0029.0345.00-37.9350.0048.1525.0015.0013.0419.2316.13-68.89135.71-29.5555.9129.6618.629.8712.65-186.23-236.97-11.353.8118.6716.5713.4913.3816.488.209.06
-----------------------------------
-----------------------------------
50505050.55151.852.452.953.954.355.155.655.85656.65756.95757.157.2357.2457.4757.657.7159.6365.7365.7765.965.72000000
-----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Cochlear Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Cochlear is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (B)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (B)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (B)
TOTAL CAPITAL (B)
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                         
16.11319.233.823.23110.543.975.9106.187.183.436.78042.872.468.552.756.172.2175.4289.5461.578.6930609.6629.3555.5513.6
11.415.418.21731.842.569.356.95465.696.1116.9143.8153.3159.5165.9144.7187.6201.3236.73268.54275.36299.1299.5211.4262.1308.4388.4425.3
0.40.10000021.713.517.413.326.233.623.958.976.350.122.422.316.6219.624.0627.232.493.5103.48269.176.7
5.88.113.611.414.127.136.44544.849.176.891.999.2105.9104.4106.1101.3131.6128.6145.86154.1160.01167.4195.4223.8216.1270.2311.5391.6
1.61.71.51.82.95.871212.212.95.95.48.88.282.39.19.21112.617.6125.3836.992929.118.838.837.13744.9
0.040.040.050.060.070.110.120.180.20.250.280.320.320.370.450.430.370.410.420.490.540.590.580.641.481.231.331.361.45
6.26.36.77.210.312.520202016.430.840.643.257.449.669.459.665.975.880.8186.88120.11128.4166.5438.8428.5439.2447.2517.2
0000000000000000000013.7615.0615.847.894.9226.8187.9188.1181.3
0.30.30.30.30.50.30.29.89.610.10.46.71220.525.117.211.80.95.50.061.510.912.13.35000.91.3
000000007.2191.819.913.921.234.75249.455.664.863.958.0352.9872.8781.7155.6139.4118.2135.4188193.3
0000000000185.4182.4187.7173.6159.9159.1151.1171170.3170.5171.36267.1263.6268.8270.9267.3257.1256.1257.7
6.56.59.511.4119.81721.327.336.530.318.521.621.917.316.150.556.752.876.9787.8674.3581.1102.2149.2155.3118.5126.9142.2
0.010.010.020.020.020.020.040.050.060.250.270.260.290.310.30.310.330.360.370.390.410.550.570.741.11.21.141.211.29
0.050.050.070.080.090.130.160.230.260.510.550.590.610.680.750.740.70.760.790.880.961.141.161.382.582.432.472.572.75
                                                         
0.010.010.010.010.010.010.020.020.050.050.070.070.090.10.120.120.130.130.140.150.160.170.170.181.271.281.281.251.2
00000000000000000000000000000
14.318.924.427.734.944.660.596.688.3110.4137.9181.5223.3269.2326.4393317309.8185.1264.34333.8422.8510.6608.9174.4423.5531.5650.1775.5
-0.8-0.62.700000002.99.313-2.4-5.1-9.5-53.2-71.70-53.09-44.18-48.27-72.6-64.2-42.4-48.3-76.4-71.7-52.8
000000000000000000000-0.25-0.2-1.1-2.937.8-46-66-86.4
0.020.020.030.030.040.060.080.120.140.160.210.260.320.370.440.510.390.370.330.360.450.540.610.731.41.691.691.761.84
11.912.114.817.821.930.521.129.331.746.557.361.960.864.970.88598.480.678.699.86110.35130.91140.5160.8159.3202.9232.4270.4303.2
00000000000000000031.143.2245.4952.4157.369.554.487.9101.6146.4150.5
13.613.219.127.126.132.73855.148.876.275.656.348.752.368.678.4117.8107.956.792.0491.2878.6186.2125.9184.779.8114.9122136.2
00000000000000000000000000000
3.82.32.73.52.49.724.31525.964.270.5161.315.4073.86045.73.33.1168.163.9884.693.73.3419.131.978.739.241.6
29.327.636.648.450.472.983.499.4106.4186.9203.4279.5124.9117.2213.2223.4261.9191.8169.5403.28251.1346.62287.7359.5817.5402.5527.6578631.5
0.100000000139.3125.537.6154.5188.682.9319.9167.2234.344.55189.26134.24144178.3285.4232.4175.2162.6202.1
0000000000000.50.2000006.357.125.848.15.514.150.622.418.318.9
0.30.40.40.50.50.61.611.512.713.67.27.88.69.217.311.335.848.65665.8361.32106.03106.311057.25154.26152.1
0.40.40.40.50.50.61.611.512.7152.9132.745.4163.6198100.214.355.7215.8290.3116.73257.71246.1258.4293.8356.7334251.8241.9273.1
0.030.030.040.050.050.070.090.110.120.340.340.320.290.320.310.240.320.410.460.520.510.590.550.651.170.740.780.820.9
0.050.050.070.080.090.130.160.230.260.50.540.590.610.680.750.740.710.770.790.880.961.141.161.382.582.432.472.582.75
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Cochlear provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Cochlear's financial health and stability.

Assets

Cochlear's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Cochlear must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Cochlear after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Cochlear's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (B)
CASH FLOW FROM FINANCING ACTIVITIES (B)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0000000000000000000000000323289300
0000000000000000000000000686471
00000000000000000000000003545-14
1111-21-313342341023323545830111430
0000000000000000000000000-43-723
000000-100-2-6-8-11-9-9-6-6-7-10-7-10-8-8-5-10-12-8-9
-3-4-3-8-12-16-12-17-21-19-27-56-53-46-51-50-41-39-24-32-80-78-101-90-80-14-26-79
19614251119078499851768414617920116869111188185259258296-157265376362
-1-2-2-4-5-5-17-10-13-8-15-26-29-46-92-90-37-50-31-28-37-71-49-114-130-66-77-95
-4-2-2-4-5-5-17-10-13-203-14-37-39-46-9239-37-50-31-28-50-135-55-137-509279-138-125
-300000000-1950-10-10001300000-12-64-5-23-379346-61-29
0000000000000000000000000000
2000-2814-810176-2619-2516-32-93210667-25-2026-7133266-421-25-72
00000000.010.0300.0200.010.010.0200-0000.010.0100.011.080-0-0.04
-0-0.01-0.01-0.01-0.02-0.01-0-0.03-00.13-0.06-0.04-0.09-0.06-0.12-0.21-0.13-0.04-0.08-0.15-0.13-0.11-0.23-0.141.15-0.5-0.22-0.31
00000000000000000000000002-1-10
-4-6-6-8-17-18-21-33-42-42-49-60-77-89-107-118-136-142-144-123-120-143-161-181-193-75-194-197
34723471343-31291001466213510124119228520797147241273356334400388324416347
17.94.21221.55.314.3-16.268.335.790.636.650.455.499.987.1110.8130.919.379.5160.27147.56188.7208.4181.4-288.3198.7299.3266.5
0000000000000000000000000000

Cochlear stock margins

The Cochlear margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cochlear. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cochlear.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cochlear's sales revenue. A higher gross margin percentage indicates that the Cochlear retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cochlear's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cochlear's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cochlear's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cochlear. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cochlear's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cochlear Margin History

Cochlear Gross marginCochlear Profit marginCochlear EBIT marginCochlear Profit margin
2030e75.84 %0 %19.04 %
2029e75.84 %25.48 %18.93 %
2028e75.84 %25.31 %18.9 %
2027e75.84 %24.18 %18.11 %
2026e75.84 %23.48 %17.58 %
2025e75.84 %22.68 %17.03 %
202475.84 %23.78 %15.96 %
202375.07 %21.26 %15.53 %
202275.86 %23.9 %17.54 %
202173.38 %23.76 %21.8 %
202074.54 %18.25 %-18.04 %
201975.85 %25.2 %19.39 %
201873.72 %25.52 %18.02 %
201771.94 %25.85 %17.83 %
201671.93 %23.9 %16.71 %
201571.35 %23.27 %15.76 %
201469.35 %19.17 %11.64 %
201372.55 %24.3 %17.62 %
201274.53 %28.31 %7.29 %
201172.62 %30.5 %22.25 %
201073.31 %30.69 %21.12 %
200972.12 %25.49 %18.79 %
200872.31 %27.42 %19.15 %
200771.17 %27.46 %17.89 %
200671.04 %23.99 %17.69 %
200573.8 %22.96 %15.64 %

Cochlear Stock Sales Revenue, EBIT, Earnings per Share

The Cochlear earnings per share therefore indicates how much revenue Cochlear has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cochlear earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cochlear's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cochlear’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cochlear's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cochlear Revenue, EBIT and net profit per share

DateCochlear Sales per ShareCochlear EBIT per shareCochlear Earnings per Share
2030e58.99 undefined0 undefined11.23 undefined
2029e54.4 undefined0 undefined10.3 undefined
2028e50.38 undefined0 undefined9.52 undefined
2027e45.09 undefined0 undefined8.17 undefined
2026e41.02 undefined0 undefined7.21 undefined
2025e37.29 undefined0 undefined6.35 undefined
202434.02 undefined8.09 undefined5.43 undefined
202329.38 undefined6.25 undefined4.56 undefined
202225.06 undefined5.99 undefined4.4 undefined
202122.78 undefined5.41 undefined4.97 undefined
202022.14 undefined4.04 undefined-4 undefined
201924.72 undefined6.23 undefined4.79 undefined
201823.67 undefined6.04 undefined4.27 undefined
201721.82 undefined5.64 undefined3.89 undefined
201619.75 undefined4.72 undefined3.3 undefined
201516.17 undefined3.76 undefined2.55 undefined
201414.1 undefined2.7 undefined1.64 undefined
201313.21 undefined3.21 undefined2.33 undefined
201213.69 undefined3.88 undefined1 undefined
201114.2 undefined4.33 undefined3.16 undefined
201012.98 undefined3.98 undefined2.74 undefined
200912.41 undefined3.16 undefined2.33 undefined
200810.78 undefined2.96 undefined2.06 undefined
200710.06 undefined2.76 undefined1.8 undefined
20068.21 undefined1.97 undefined1.45 undefined
20056.42 undefined1.47 undefined1 undefined

Cochlear business model

Cochlear Ltd is an Australian-based medical technology company founded in 1981 by engineer Professor Graeme Clark. The company specializes in Cochlear implant systems and other hearing devices. Cochlear Ltd offers accessories, services, and rehabilitation training for individuals with hearing impairments. The company's products are available for both children and adults with varying degrees of hearing loss. Cochlear Ltd operates in different sectors, including Cochlear implant systems, hearing aids, and wireless accessories and streaming systems under the brand names Nucleus® and Baha®. Nucleus® systems utilize a fully implantable cochlear implant and external speech processor to convert sound into electrical signals for interpretation by the brain. Baha® systems are bone-anchored hearing devices for individuals with unilateral to moderate hearing impairments. Cochlear Ltd also provides wireless accessories and streaming systems to connect devices like mobile phones, TVs, and music players to the hearing aids and cochlear implants, improving hearing performance and enhancing social lives. The company has a strong global presence, operating in over 100 countries with headquarters in Australia, multiple production facilities, and research centers. Cochlear Ltd has received numerous awards and recognition for its products and services and is committed to researching and developing new therapies and technologies to improve the lives of individuals with hearing impairments. Cochlear is one of the most popular companies on Eulerpool.com.

Cochlear SWOT Analysis

Strengths

Cochlear Ltd possesses several key strengths that contribute to its success in the market. Firstly, the company is a pioneer and leader in the field of implantable hearing solutions, with over 30 years of experience. This enables them to offer innovative and technologically advanced products that provide significant benefits to individuals with hearing loss.

Moreover, Cochlear has established a strong global presence with a wide distribution network spanning across more than 100 countries. This allows them to reach a large customer base and maintain strong relationships with healthcare professionals, ensuring accessibility and support for their products. Additionally, the company has a robust intellectual property portfolio, providing them with a competitive advantage in the market.

Weaknesses

Despite its strengths, Cochlear Ltd faces a few weaknesses that could pose challenges. One significant weakness is the high cost associated with their implantable hearing solutions. This can limit their accessibility to a substantial portion of the population, particularly in developing countries or regions where healthcare budgets are constrained.

Another weakness lies in the complexity of the surgical procedure required for implanting their hearing devices. This could deter potential customers who might prefer less invasive options or who are reluctant to undergo surgery. Additionally, as a specialized medical device company, Cochlear relies heavily on regulatory approvals, which can lead to delays in product launches and market entry.

Opportunities

Cochlear Ltd operates in an industry with several significant opportunities. Firstly, the growing global prevalence of hearing loss, coupled with an aging population, presents a substantial market opportunity for the company. They can leverage their expertise and portfolio to address the unmet needs of individuals with hearing impairment worldwide.

Furthermore, advancements in technology and digital healthcare offer opportunities for Cochlear to develop innovative solutions that improve user experience and convenience. The increasing adoption of telehealth and remote patient monitoring also opens new avenues for Cochlear to provide virtual support and services to its customers, enhancing accessibility and convenience.

Threats

Cochlear Ltd operates in a competitive market with several threats that could impact its business. One significant threat is the presence of well-established competitors in the hearing solutions industry who have the financial resources and R&D capabilities to develop competitive products. This intensifies the need for Cochlear to maintain its focus on innovation and differentiation.

Additionally, changes in healthcare policies and reimbursement systems can pose a threat to Cochlear's financial performance. Reimbursement cuts or changes in coverage policies may affect the affordability and accessibility of the company's products, impacting market demand. Lastly, economic downturns or financial crises can also have an adverse effect on Cochlear's business, as discretionary healthcare spending may decline during such periods.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Cochlear Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Cochlear historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Cochlear shares outstanding

The number of shares was Cochlear in 2024 — This indicates how many shares 65.721 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cochlear earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cochlear's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cochlear’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cochlear's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cochlear dividend history and estimates

In 2024, Cochlear paid a dividend amounting to 5.42 AUD. Dividend means that Cochlear distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Cochlear provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Cochlear’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Cochlear's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Cochlear Dividend History

DateCochlear Dividend
2030e5.7 undefined
2029e5.69 undefined
2028e5.69 undefined
2027e5.7 undefined
2026e5.69 undefined
2025e5.68 undefined
20245.42 undefined
20234.06 undefined
20223.25 undefined
20212.55 undefined
20202.29 undefined
20194.71 undefined
20184.29 undefined
20173.86 undefined
20163.29 undefined
20152.46 undefined
20142.65 undefined
20132.9 undefined
20122.95 undefined
20112.88 undefined
20102.68 undefined
20092.5 undefined
20082.14 undefined
20071.79 undefined
20061.43 undefined
20051.14 undefined

Cochlear dividend payout ratio

In 2024, Cochlear had a payout ratio of 66.59%. The payout ratio indicates the percentage of the company's profits that Cochlear distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Cochlear represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Cochlear could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Cochlear's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Cochlear Payout Ratio History

DateCochlear Payout ratio
2030e70.33 %
2029e70.48 %
2028e70.78 %
2027e69.73 %
2026e70.93 %
2025e71.67 %
202466.59 %
202374.52 %
202273.91 %
202151.34 %
2020-57.2 %
201998.32 %
2018100.6 %
201799.12 %
201699.56 %
201596.67 %
2014161.52 %
2013124.9 %
2012294.71 %
201191.14 %
201097.71 %
2009107.3 %
2008103.52 %
200799.21 %
200698.52 %
2005114.29 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Cochlear.

Cochlear latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20243.14 3.13  (-0.23 %)2025 Q2
6/30/20243.14 2.96  (-5.63 %)2024 Q4
12/31/20232.91 2.92  (0.45 %)2024 Q2
6/30/20232.46 2.48  (0.73 %)2023 Q4
12/31/20222.02 2.15  (6.35 %)2023 Q2
6/30/20221.94 1.82  (-6.11 %)2022 Q4
12/31/20211.99 2.4  (20.09 %)2022 Q2
6/30/20211.79 1.7  (-5.46 %)2021 Q4
12/31/20201.46 1.91  (30.59 %)2021 Q2
6/30/20200.36 0.28  (-20.71 %)2020 Q4
1
2
3

Eulerpool ESG Scorecard© for the Cochlear stock

Eulerpool World ESG Rating (EESG©)

71/ 100

🌱 Environment

64

👫 Social

99

🏛️ Governance

51

Environment

Scope 1 - Direct Emissions
916
Scope 2 - Indirect emissions from purchased energy
2,401
Scope 3 - Indirect emissions within the value chain
1,046
Total CO₂ emissions
3,316
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees53
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Cochlear shareholders

%
Name
Stocks
Change
Date
5.72446 % APG Asset Management N.V.3,743,798147,2858/22/2024
5.23821 % The Vanguard Group, Inc.3,425,792143,1347/26/2024
5.01416 % Pinnacle Investment Management Group Ltd3,279,25939,53311/5/2024
4.67750 % State Street Global Advisors Australia Ltd.3,059,0852,883,7985/16/2024
2.18286 % Norges Bank Investment Management (NBIM)1,427,591274,75212/31/2024
2.02267 % BlackRock Institutional Trust Company, N.A.1,322,827291/31/2025
1.72084 % Stewart Investors1,125,428012/31/2024
1.62612 % Vanguard Investments Australia Ltd.1,063,48121,70712/31/2024
1.26569 % State Street Global Advisors (US)827,761725,8635/16/2024
0.77565 % Schroder Investment Management (Singapore) Ltd.507,2731,88511/30/2024
1
2
3
4
5
...
10

Cochlear Executives and Management Board

Mr. Diggory Howitt

(56)
Cochlear President, Chief Executive Officer, Executive Director
Compensation 5.08 M

Mr. Jan Janssen

Cochlear Chief Technology Officer
Compensation 2.22 M

Mr. Stuart Sayers

Cochlear President, Asia Pacific & Latin America
Compensation 1.8 M

Mr. Anthony Bishop

Cochlear President - EMEA
Compensation 1.45 M

Ms. Alison Deans

(57)
Cochlear Non-Executive Independent Chairman of the Board
Compensation 596,779
1
2
3
4
...
5

Most common questions regarding Cochlear

What values and corporate philosophy does Cochlear represent?

Cochlear Ltd represents a strong set of values and corporate philosophy. The company is committed to improving the lives of people with hearing loss by providing innovative and reliable solutions. Cochlear believes in putting their customers first and delivering exceptional quality products and services. With a focus on continuous improvement, the company is dedicated to research and development to drive technological advancements in the field of hearing implants. Cochlear's corporate philosophy is centered around integrity, collaboration, and social responsibility. By embracing diversity and fostering a culture of inclusivity, Cochlear strives to make a positive impact on individuals and communities worldwide.

In which countries and regions is Cochlear primarily present?

Cochlear Ltd is primarily present in various countries and regions worldwide. The company operates in over 100 countries, including but not limited to Australia, the United States, Europe, Asia-Pacific, and Latin America. With its global presence, Cochlear Ltd has established itself as a leading provider of innovative hearing solutions and implantable hearing devices. Through its extensive network and collaborations, the company strives to enhance the lives of individuals with hearing loss across the world by providing advanced hearing technology and support.

What significant milestones has the company Cochlear achieved?

Cochlear Ltd has achieved several significant milestones. One of the notable milestones includes the development and introduction of the world's first commercially successful cochlear implant in 1982. This breakthrough technology revolutionized the treatment of hearing loss for millions of people worldwide. Another key milestone for Cochlear Ltd was the successful launch of the Nucleus 6 Sound Processor, which offered enhanced hearing performance and wireless connectivity options. The company also made significant progress in expanding its global footprint, establishing subsidiaries and partnerships in different regions. Additionally, Cochlear Ltd received numerous industry recognitions and awards for its innovative products and contribution to the field of hearing healthcare.

What is the history and background of the company Cochlear?

Cochlear Ltd is an Australian medical device company specializing in hearing implant solutions. Founded in 1981, it has a rich history and remarkable achievements in the field of implantable hearing devices. Cochlear is globally recognized for its groundbreaking advancements in the development and commercialization of cochlear implant technology. By providing solutions for people with profound hearing loss, Cochlear has improved the lives of millions worldwide. With a strong commitment to innovation and a dedicated team of experts, Cochlear remains at the forefront of the industry, continuously striving to enhance hearing experiences and transform lives through its state-of-the-art products and services.

Who are the main competitors of Cochlear in the market?

The main competitors of Cochlear Ltd in the market include major companies like Medtronic, Sonova Holding AG, and William Demant Holding A/S.

In which industries is Cochlear primarily active?

Cochlear Ltd is primarily active in the healthcare and medical device industries.

What is the business model of Cochlear?

Cochlear Ltd operates under a distinctive business model. As a global leader in the development and manufacturing of hearing solutions, the company primarily focuses on designing, producing, and marketing cochlear implant devices. Cochlear implants are electronic devices that provide a sense of sound to individuals with severe hearing loss or deafness. With a commitment to continuous innovation and superior quality, Cochlear Ltd offers a wide range of products and services that cater to the needs of patients, healthcare professionals, and hearing implant clinics worldwide. Through its robust business model, Cochlear Ltd aims to improve the lives of individuals with hearing challenges by providing cutting-edge and life-changing hearing solutions.

What is the P/E ratio of Cochlear 2025?

The P/E ratio cannot be calculated for Cochlear at the moment.

What is the P/S ratio of Cochlear 2025?

The P/S cannot be calculated for Cochlear currently.

What is the Quality Investing of Cochlear?

The Quality Investing for Cochlear is 9/10.

What is the revenue of Cochlear 2025?

The expected Cochlear revenue is 2.44 B AUD.

How high is the profit of Cochlear 2025?

The expected Cochlear profit is 415.28 M AUD.

What is the business model of Cochlear

Cochlear Ltd is a leading provider of innovative medical solutions for people with hearing loss. The company is headquartered in Sydney, Australia and operates in over 100 countries worldwide. Cochlear specializes in imitating the functionality of the human ear to provide a better hearing experience for those with hearing loss. They offer a wide range of products and services including cochlear implants, audioprocessors, cochlear replacement parts, and hearing aids. Cochlear implants are one of the company's main products, designed to help those with severe to profound hearing loss regain their ability to hear. The implant is an electronic device that bypasses the inner ear by sending signals directly to the auditory nerve. In addition to cochlear implants and audioprocessors, Cochlear also offers wireless accessory devices such as TV streamers to enhance the listening experience. They have a dedicated department for manufacturing hearing aids called "Cochlear Devices," which are designed for individuals with mild to moderate hearing loss. The company is always working on new technologies to improve the listening experience for individuals with hearing loss, including their latest innovation, the Cochlear sound processor, which utilizes artificial intelligence to automatically adapt to different environments for optimal sound quality. Cochlear provides a range of services to support their customers, including training and support for healthcare professionals who implant or adjust Cochlear devices. They collaborate with customers, clinics, research institutions, and universities to develop the latest advancements in technology to improve the lives of individuals with hearing loss. Cochlear's business model is focused on promoting health and well-being, providing innovative hearing device and implant technologies, and comprehensive services to ensure an excellent patient experience. They are committed to playing a leading role in the treatment of hearing loss and helping people worldwide overcome their hearing challenges.

What is the Cochlear dividend?

Cochlear pays a dividend of 3.25 AUD distributed over 2 payouts per year.

How often does Cochlear pay dividends?

Cochlear pays out a dividend 2 times a year.

What is the Cochlear ISIN?

The ISIN of Cochlear is AU000000COH5.

What is the Cochlear WKN?

The WKN of Cochlear is 898321.

What is the Cochlear ticker?

The ticker of Cochlear is COH.AX.

How much dividend does Cochlear pay?

Over the past 12 months, Cochlear paid a dividend of 5.42 AUD . This corresponds to a dividend yield of about . For the coming 12 months, Cochlear is expected to pay a dividend of 5.69 AUD.

What is the dividend yield of Cochlear?

The current dividend yield of Cochlear is .

When does Cochlear pay dividends?

Cochlear pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Cochlear?

Cochlear paid dividends every year for the past 26 years.

What is the dividend of Cochlear?

For the upcoming 12 months, dividends amounting to 5.69 AUD are expected. This corresponds to a dividend yield of 2.27 %.

In which sector is Cochlear located?

Cochlear is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cochlear kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cochlear from 4/14/2025 amounting to 2.887 AUD, you needed to have the stock in your portfolio before the ex-date on 3/20/2025.

When did Cochlear pay the last dividend?

The last dividend was paid out on 4/14/2025.

What was the dividend of Cochlear in the year 2024?

In the year 2024, Cochlear distributed 4.058 AUD as dividends.

In which currency does Cochlear pay out the dividend?

The dividends of Cochlear are distributed in AUD.

All fundamentals about Cochlear

Our stock analysis for Cochlear Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cochlear Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.